Latigo Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
LTGO$13.33-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine months ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(69,707) | $(71,583) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash lease expense | 442 | 323 |
| Depreciation | 152 | 200 |
| Stock-based compensation expense | 6,657 | 4,977 |
| Change in fair value of preferred stock tranche liability | — | 1,674 |
| Change in fair value of derivative liability | (5,148) | |
| Amortization of debt discount and issuance costs and non-cash interest expense | 975 | — |
| Loss on extinguishment of debt | 4,581 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (833) | (1,775) |
| Other assets | 92 | 266 |
| Accounts payable | 70 | (246) |
| Accrued expenses and other current liabilities | (4,694) | 3,848 |
| Operating lease liabilities | (461) | (314) |
| Net cash used in operating activities | (67,874) | (62,630) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (146) | (135) |
| Net cash used in investing activities | (146) | (135) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs paid | — | 149,379 |
| Proceeds from issuance of convertible notes, net of issuance costs paid | 34,832 | — |
| Proceeds from issuance of common stock upon exercise of stock options | 496 | 108 |
| Proceeds from IPO, net of underwriting discounts, commissions and offering costs paid | 364,380 | — |
| Net cash provided by financing activities | 399,708 | 149,487 |
| Net increase in cash, cash equivalents and restricted cash | 331,688 | 86,722 |
| Cash, cash equivalents and restricted cash, beginning of period | 69,721 | 17,918 |
| Cash, cash equivalents and restricted cash, end of period | $401,409 | $104,640 |
| Supplemental cash flow information: | ||
| Right-of-use assets obtained in exchange for operating lease liabilities | $959 | $310 |
| Supplemental disclosure for non-cash investing and financing activities: | ||
| Settlement of Series B redeemable convertible preferred stock tranche liability | $— | $2,132 |
| Conversion of redeemable convertible preferred stock to common stock upon IPO | $288,582 | $— |
| Conversion of convertible notes to common stock upon IPO | $35,240 | $— |
| Reclassification from liability to equity upon vesting of early exercised stock options | $— | $250 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.